Stay up-to-date with the latest news and information from the life insurance industry by subscribing to Insights, our monthly newsletter.
Your Privacy Choices | Privacy Notices | Privacy Shield | Terms | Accessibility | Language Assistance / Non-Discrimination Notice | Asistencia de Idiomas / Aviso de no Discriminación | 語言協助 / 不䈚視通知
Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks — ® and ™ — are the property of their respective owners. © 2000-2024 Quest Diagnostics Incorporated. All rights reserved.
Recent news suggests that the United States Preventative Service Task Force will release new guidelines stating that healthy men should no longer receive a P.S.A. blood test to screen for prostate cancer in the general population.
The United States Preventive Services Task Force is an independent panel of experts in prevention and primary care appointed by the Department of Health and Human Services to review cost effective clinical preventive health care services.
ExamOne is currently reviewing the USPSTF recommendation and the medical research behind their decision in regards to the current insurance medicine utility of the PSA test in the life insurance population.
We will keep you informed as we complete our review. If you have any questions, please contact your Strategic Account Executive.